希腊动脉粥样硬化学会血脂异常诊断和治疗指南执行摘要 - 2023 年

IF 1.4 Q3 PERIPHERAL VASCULAR DISEASE
Katsiki N , Filippatos Td , Vlachopoulos C , Panagiotakos D , Milionis H , Tselepis A , Garoufi A , Rallidis L , Richter D , Nomikos T , Kolovou G , Kypreos K , Chrysohoou C , Tziomalos K , Skoumas I , Koutagiar I , Attilakos A , Papagianni M , Boutari C , Kotsis V , Liberopoulos E
{"title":"希腊动脉粥样硬化学会血脂异常诊断和治疗指南执行摘要 - 2023 年","authors":"Katsiki N ,&nbsp;Filippatos Td ,&nbsp;Vlachopoulos C ,&nbsp;Panagiotakos D ,&nbsp;Milionis H ,&nbsp;Tselepis A ,&nbsp;Garoufi A ,&nbsp;Rallidis L ,&nbsp;Richter D ,&nbsp;Nomikos T ,&nbsp;Kolovou G ,&nbsp;Kypreos K ,&nbsp;Chrysohoou C ,&nbsp;Tziomalos K ,&nbsp;Skoumas I ,&nbsp;Koutagiar I ,&nbsp;Attilakos A ,&nbsp;Papagianni M ,&nbsp;Boutari C ,&nbsp;Kotsis V ,&nbsp;Liberopoulos E","doi":"10.1016/j.athplu.2024.01.004","DOIUrl":null,"url":null,"abstract":"<div><p>Atherosclerotic cardiovascular disease (ASCVD) remains the main cause of death worldwide, and thus its prevention, early diagnosis and treatment is of paramount importance. Dyslipidemia represents a major ASCVD risk factor that should be adequately managed at different clinical settings. 2023 guidelines of the Hellenic Atherosclerosis Society focus on the assessment of ASCVD risk, laboratory evaluation of dyslipidemias, new and emerging lipid-lowering drugs, as well as diagnosis and treatment of lipid disorders in women, the elderly and in patients with familial hypercholesterolemia, acute coronary syndromes, heart failure, stroke, chronic kidney disease, diabetes, autoimmune diseases, and non-alcoholic fatty liver disease. Statin intolerance is also discussed.</p></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"55 ","pages":"Pages 74-92"},"PeriodicalIF":1.4000,"publicationDate":"2024-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266708952400004X/pdfft?md5=9461b24442f342030f6ea703f518b6fb&pid=1-s2.0-S266708952400004X-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023\",\"authors\":\"Katsiki N ,&nbsp;Filippatos Td ,&nbsp;Vlachopoulos C ,&nbsp;Panagiotakos D ,&nbsp;Milionis H ,&nbsp;Tselepis A ,&nbsp;Garoufi A ,&nbsp;Rallidis L ,&nbsp;Richter D ,&nbsp;Nomikos T ,&nbsp;Kolovou G ,&nbsp;Kypreos K ,&nbsp;Chrysohoou C ,&nbsp;Tziomalos K ,&nbsp;Skoumas I ,&nbsp;Koutagiar I ,&nbsp;Attilakos A ,&nbsp;Papagianni M ,&nbsp;Boutari C ,&nbsp;Kotsis V ,&nbsp;Liberopoulos E\",\"doi\":\"10.1016/j.athplu.2024.01.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Atherosclerotic cardiovascular disease (ASCVD) remains the main cause of death worldwide, and thus its prevention, early diagnosis and treatment is of paramount importance. Dyslipidemia represents a major ASCVD risk factor that should be adequately managed at different clinical settings. 2023 guidelines of the Hellenic Atherosclerosis Society focus on the assessment of ASCVD risk, laboratory evaluation of dyslipidemias, new and emerging lipid-lowering drugs, as well as diagnosis and treatment of lipid disorders in women, the elderly and in patients with familial hypercholesterolemia, acute coronary syndromes, heart failure, stroke, chronic kidney disease, diabetes, autoimmune diseases, and non-alcoholic fatty liver disease. Statin intolerance is also discussed.</p></div>\",\"PeriodicalId\":72324,\"journal\":{\"name\":\"Atherosclerosis plus\",\"volume\":\"55 \",\"pages\":\"Pages 74-92\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-02-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S266708952400004X/pdfft?md5=9461b24442f342030f6ea703f518b6fb&pid=1-s2.0-S266708952400004X-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Atherosclerosis plus\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S266708952400004X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Atherosclerosis plus","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266708952400004X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

摘要

动脉粥样硬化性心血管疾病(ASCVD)仍然是全球的主要死因,因此其预防、早期诊断和治疗至关重要。血脂异常是动脉粥样硬化性心血管疾病的一个主要风险因素,应在不同的临床环境中加以适当管理。希腊动脉粥样硬化学会 2023 年指南重点关注 ASCVD 风险评估、血脂异常的实验室评估、新出现的降脂药物,以及女性、老年人和家族性高胆固醇血症、急性冠状动脉综合征、心力衰竭、中风、慢性肾病、糖尿病、自身免疫性疾病和非酒精性脂肪肝患者的血脂紊乱诊断和治疗。此外,还讨论了他汀类药物不耐受的问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023

Atherosclerotic cardiovascular disease (ASCVD) remains the main cause of death worldwide, and thus its prevention, early diagnosis and treatment is of paramount importance. Dyslipidemia represents a major ASCVD risk factor that should be adequately managed at different clinical settings. 2023 guidelines of the Hellenic Atherosclerosis Society focus on the assessment of ASCVD risk, laboratory evaluation of dyslipidemias, new and emerging lipid-lowering drugs, as well as diagnosis and treatment of lipid disorders in women, the elderly and in patients with familial hypercholesterolemia, acute coronary syndromes, heart failure, stroke, chronic kidney disease, diabetes, autoimmune diseases, and non-alcoholic fatty liver disease. Statin intolerance is also discussed.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Atherosclerosis plus
Atherosclerosis plus Cardiology and Cardiovascular Medicine
CiteScore
2.60
自引率
0.00%
发文量
0
审稿时长
66 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信